Halozyme Therapeutics (HALO) said Monday that Johnson & Johnson's (JNJ) Janssen-Cilag International has received a positive opinion in Europe recommending an extension of marketing authorization for a subcutaneous formulation of Rybrevant in treating non-small cell lung cancer.
The positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use is for Rybrevant in combination with Lazcluze and as a monotherapy, Halozyme said.
The company said subcutaneous Rybrevant is co-formulated with its Enhanze drug delivery technology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.